Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AWAWU E IGBINADOLOR

Allopathic & Osteopathic Physicians Internal Medicine Adolescent Medicine

NPI
1386658128
CMS profile
334690
Location
MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,264.02

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,528.15 7
Food and Beverage $735.87 7

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Alnylam Pharmaceuticals Inc. $2,070.10 7
Novartis Pharmaceuticals Corporation $1,054.59 5
Amgen Inc. $125.00 1
AstraZeneca Pharmaceuticals LP $14.33 1

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AWAWU E IGBINADOLOR

NPI 1386658128 · CMS profile ID 334690

Allopathic & Osteopathic Physicians / Internal Medicine / Adolescent Medicine

MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $3,264.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $235.6909/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785835 CMS
Novartis Pharmaceuticals Corporation $526.1309/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785837 CMS
Novartis Pharmaceuticals Corporation $9.0909/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785839 CMS
Novartis Pharmaceuticals Corporation $111.1509/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785843 CMS
Novartis Pharmaceuticals Corporation $172.5309/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785841 CMS
Alnylam Pharmaceuticals Inc. $371.7404/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853427 CMS
Alnylam Pharmaceuticals Inc. $151.9704/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853431 CMS
Alnylam Pharmaceuticals Inc. $82.8604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853433 CMS
Alnylam Pharmaceuticals Inc. $105.0004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853435 CMS
Alnylam Pharmaceuticals Inc. $125.0004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853437 CMS
Alnylam Pharmaceuticals Inc. $1,081.5604/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853425 CMS
Alnylam Pharmaceuticals Inc. $151.9704/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853429 CMS
AstraZeneca Pharmaceuticals LP $14.3301/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104408293 CMS
Amgen Inc. $125.0001/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111604726 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $825.59 19
PY2020 $250.77 11
PY2021 $613.59 23
PY2022 $635.48 38
PY2023 $1,376.29 8
PY2024 $3,264.02 14
PY2025 $15.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,807,545.77 332
PY2024 Recipient $24,803.18 2
PY2024 Principal investigator $5,575,092.65 467
PY2023 Recipient $5,441.70 12
PY2023 Principal investigator $4,002,304.15 759
PY2022 Recipient $99,385.00 2
PY2022 Principal investigator $3,185,482.26 500
PY2021 Recipient $421,014.16 3
PY2021 Principal investigator $3,556,229.85 34
PY2020 Recipient $145,488.66 2
PY2019 Principal investigator $9,471.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

332 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $19,416.63 12/31/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929099
Principal investigator 1 Merck Sharp & Dohme LLC $274.40 12/31/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929101
Principal investigator 1 Amgen Inc. $19,300.00 12/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2) No dispute reported 06/30/2026 1246644803
Principal investigator 1 Amgen Inc. $20,348.00 12/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity No dispute reported 06/30/2026 1246644807
Principal investigator 1 Genentech, Inc. $2,838.00 12/23/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC No dispute reported 06/30/2026 1211626327
Principal investigator 1 Eli Lilly and Company $10,000.00 12/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES (SYNERGY-OUTCOMES); N1T-MC-TZ01; N1T-MC-RT01 No dispute reported 06/30/2026 1187887774
Principal investigator 1 Genentech, Inc. $1,000.00 12/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC No dispute reported 06/30/2026 1211626315
Principal investigator 1 Genentech, Inc. $1,000.00 12/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC No dispute reported 06/30/2026 1211626318
Principal investigator 1 Genentech, Inc. $1,500.00 12/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC No dispute reported 06/30/2026 1211626321
Principal investigator 1 PFIZER INC. $432.00 12/20/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228746312
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,643.57 12/19/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514720
Principal investigator 1 SANOFI PASTEUR INC. $503.86 12/19/2025 Non-covered Recipient Entity
Monroe Biomedical Research Monroe
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers No dispute reported 06/30/2026 1226102394
Principal investigator 1 Verona Pharma, Inc. $850.00 12/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891527
Principal investigator 1 Verona Pharma, Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891529
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288080
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288082
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288084
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288212
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288214
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288216
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288270
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288272
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288274
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288276
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288278
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288280
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288282
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288284
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288286
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288288
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288290
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288302
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288304
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288306
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288308
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288448
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288450
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288452
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288454
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288456
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288461
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288464
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288466
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288468
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288470
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288472
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288474
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288476
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288478
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288480
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288482
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288484
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288486
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288488
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288490
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288492
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288494
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288496
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288498
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288500
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288502
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288504
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288506
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288508
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288510
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288512
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288514
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288516
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288518
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288520
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288522
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288524
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288526
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288528
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288530
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288532
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288562
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288564
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288566
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288568
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288570
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514707
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187885520
Principal investigator 1 Eli Lilly and Company $934.02 12/17/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187886584
Principal investigator 1 Verona Pharma, Inc. $328.44 12/12/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891599
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 12/10/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514672
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 12/10/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,729.80 12/10/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 12/10/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514692
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 12/10/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514716
Principal investigator 1 Alnylam Pharmaceuticals Inc. $100.00 12/10/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514732
Principal investigator 1 Alnylam Pharmaceuticals Inc. $800.00 12/10/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514742
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514700
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 12/01/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514696
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,417.60 12/01/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514747
Principal investigator 1 PFIZER INC. $1,000.00 11/29/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228737506
Principal investigator 1 SANOFI PASTEUR INC. $1,573.10 11/25/2025 Non-covered Recipient Entity
Monroe Biomedical Research Monroe
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers No dispute reported 06/30/2026 1226102354
Principal investigator 1 Merck Sharp & Dohme LLC $80,150.43 11/24/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929097
Principal investigator 1 ModernaTX, Inc. $5,882.16 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966005
Principal investigator 1 ModernaTX, Inc. $6,021.04 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966009
Principal investigator 1 ModernaTX, Inc. $5,065.20 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966011
Principal investigator 1 ModernaTX, Inc. $3,446.52 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966013
Principal investigator 1 ModernaTX, Inc. $17,451.84 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966021
Principal investigator 1 ModernaTX, Inc. $1,067.58 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966043
Principal investigator 1 ModernaTX, Inc. $17,532.45 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966063
Principal investigator 1 ModernaTX, Inc. $3,642.60 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966067
Principal investigator 1 ModernaTX, Inc. $20,710.08 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966069
Principal investigator 1 ModernaTX, Inc. $862.54 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966071
Principal investigator 1 ModernaTX, Inc. $8,524.10 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966081
Principal investigator 1 ModernaTX, Inc. $1,774.71 11/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 11/21/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $200.00 11/21/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514668
Principal investigator 1 Alnylam Pharmaceuticals Inc. $574.56 11/21/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514685
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 11/21/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514728
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,600.00 11/21/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514739
Principal investigator 1 ModernaTX, Inc. $58.59 11/21/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 11/19/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514704
Principal investigator 1 Alnylam Pharmaceuticals Inc. $800.00 11/19/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514736
Principal investigator 1 ModernaTX, Inc. $500.00 11/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,356.43 11/14/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514676
Principal investigator 1 Alnylam Pharmaceuticals Inc. $750.00 11/14/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514712
Principal investigator 1 Alnylam Pharmaceuticals Inc. $250.00 11/14/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514724
Principal investigator 1 ModernaTX, Inc. $30.00 11/07/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966041
Principal investigator 1 GlaxoSmithKline, LLC. $850.00 11/05/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT No dispute reported 06/30/2026 1192098254
Principal investigator 1 PFIZER INC. $598.00 11/04/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228739272
Principal investigator 1 Alnylam Pharmaceuticals Inc. $341.00 11/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514658
Principal investigator 1 Verona Pharma, Inc. $37,192.20 11/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891535
Principal investigator 1 Verona Pharma, Inc. $2,000.00 11/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891619
Principal investigator 1 Seqirus USA Inc $4,103.04 10/31/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810104
Principal investigator 1 Seqirus USA Inc $1,127.52 10/31/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810108
Principal investigator 1 ModernaTX, Inc. $208.07 10/29/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966037
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,652.30 10/28/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185545279
Principal investigator 1 ModernaTX, Inc. $2,177.28 10/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,199.39 10/22/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514750
Principal investigator 1 ModernaTX, Inc. $500.00 10/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966035
Principal investigator 1 ModernaTX, Inc. $30.00 10/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966055
Principal investigator 1 ModernaTX, Inc. $500.00 10/16/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966019
Principal investigator 1 ModernaTX, Inc. $5,000.00 10/16/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966065
Principal investigator 1 Seqirus USA Inc $13,500.00 10/16/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290338
Principal investigator 1 Seqirus USA Inc $3,000.00 10/16/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290344
Principal investigator 1 ModernaTX, Inc. $500.00 10/08/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966023
Principal investigator 1 ModernaTX, Inc. $30.00 10/08/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966087
Principal investigator 1 Genentech, Inc. $284.98 10/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626307
Principal investigator 1 Genentech, Inc. $850.00 10/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626311
Principal investigator 1 Verona Pharma, Inc. $328.44 10/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891585
Principal investigator 1 ModernaTX, Inc. $1,250.00 10/01/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966059
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,500.00 09/25/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190305229
Principal investigator 1 PFIZER INC. $1,794.00 09/24/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228750625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 09/19/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514627
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,900.86 09/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185545273
Principal investigator 1 ModernaTX, Inc. $4,627.53 09/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $326.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $326.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514852
Principal investigator 1 Alnylam Pharmaceuticals Inc. $101.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514856
Principal investigator 1 Alnylam Pharmaceuticals Inc. $384.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $110.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $273.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514868
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $280.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $546.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514878
Principal investigator 1 Alnylam Pharmaceuticals Inc. $341.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 09/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514888
Principal investigator 1 Verona Pharma, Inc. $850.00 09/12/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50.00 09/10/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514798
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,157.00 09/10/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185545277
Principal investigator 1 PFIZER INC. $2,160.00 09/09/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228750749
Principal investigator 1 Seqirus USA Inc $111.30 09/09/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283601
Principal investigator 1 Seqirus USA Inc $177.19 09/09/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283605
Principal investigator 1 Seqirus USA Inc $789.00 09/09/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283609
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,771.93 09/08/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190309762
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,000.00 09/05/2025 Non-covered Recipient Entity
DRUG STUDIES AMERICA
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514808
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514812
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,331.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514816
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,050.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514820
Principal investigator 1 Alnylam Pharmaceuticals Inc. $520.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,668.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,350.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,895.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514836
Principal investigator 1 Alnylam Pharmaceuticals Inc. $846.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514840
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50,425.50 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514844
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514894
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514898
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514902
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514906
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514910
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514918
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514922
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514928
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514936
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514940
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514964
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514968
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514992
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215514997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215515001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215515005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 09/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215515011
Principal investigator 1 GlaxoSmithKline, LLC. $3,499.00 09/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT No dispute reported 06/30/2026 1192098239
Principal investigator 1 GlaxoSmithKline, LLC. $16,500.00 09/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT No dispute reported 06/30/2026 1192098247
Principal investigator 1 ModernaTX, Inc. $500.00 09/02/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966073
Principal investigator 1 F. Hoffmann-La Roche AG $850.00 08/26/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626223
Principal investigator 1 AstraZeneca Pharmaceuticals LP $73,396.54 08/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185545275
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,034.60 08/20/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185545271
Principal investigator 1 Verona Pharma, Inc. $1,000.00 08/20/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891517
Principal investigator 1 ModernaTX, Inc. $180.00 08/08/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966027
Principal investigator 1 ModernaTX, Inc. $60.00 08/08/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966049
Principal investigator 1 ModernaTX, Inc. $60.00 08/08/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966057
Principal investigator 1 ModernaTX, Inc. $472.80 08/08/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50.00 08/06/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514779
Principal investigator 1 PFIZER INC. $500.00 08/05/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228766907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 08/01/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514794
Principal investigator 1 Amgen Inc. $107,384.73 08/01/2025 Non-covered Recipient Entity
CLINITIATIVE LLC CLINITIATIVE HEALTH RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246640407
Principal investigator 1 ModernaTX, Inc. $500.00 08/01/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966031
Principal investigator 1 F. Hoffmann-La Roche AG $243.00 07/31/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626232
Principal investigator 1 F. Hoffmann-La Roche AG $3,229.00 07/31/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626239
Principal investigator 1 Amgen Inc. $247,453.03 07/28/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246644799
Principal investigator 1 ModernaTX, Inc. $500.00 07/28/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 07/25/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514782
Principal investigator 1 Verona Pharma, Inc. $10,000.00 07/25/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891473
Principal investigator 1 Verona Pharma, Inc. $1,852.00 07/25/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891475
Principal investigator 1 Verona Pharma, Inc. $1,000.00 07/25/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891511
Principal investigator 1 F. Hoffmann-La Roche AG $463.07 07/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626226
Principal investigator 1 F. Hoffmann-La Roche AG $3,229.00 07/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626236
Principal investigator 1 F. Hoffmann-La Roche AG $3,229.00 07/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626242
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50.00 07/18/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50.00 07/18/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514786
Principal investigator 1 Alnylam Pharmaceuticals Inc. $150.00 07/18/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514791
Principal investigator 1 ModernaTX, Inc. $6,191.64 07/18/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $29,869.47 07/16/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514772
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $500.00 07/11/2025 Non-covered Recipient Entity
Research Mate Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067019
Principal investigator 1 PFIZER INC. $500.00 07/11/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228782280
Principal investigator 1 Amgen Inc. $25,433.65 06/26/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246644811
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,215.23 06/24/2025 Non-covered Recipient Entity
Monroe Biomedical Research, Llc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235995633
Principal investigator 1 ModernaTX, Inc. $30.00 06/20/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966033
Principal investigator 1 ModernaTX, Inc. $2,347.38 06/20/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966053
Principal investigator 1 Genentech, Inc. $66.00 06/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626245
Principal investigator 1 Genentech, Inc. $243.00 06/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626273
Principal investigator 1 Genentech, Inc. $5,649.00 06/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626280
Principal investigator 1 ModernaTX, Inc. $32,784.80 06/18/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966079
Principal investigator 1 Genentech, Inc. $2,440.11 06/12/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626256
Principal investigator 1 Genentech, Inc. $243.00 06/05/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626252
Principal investigator 1 Genentech, Inc. $1,515.97 06/05/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626268
Principal investigator 1 Genentech, Inc. $3,058.00 06/05/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626285
Principal investigator 1 Genentech, Inc. $81.00 06/05/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626293
Principal investigator 1 Genentech, Inc. $243.00 06/05/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626298
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/04/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966017
Principal investigator 1 ModernaTX, Inc. $60.00 06/04/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966025
Principal investigator 1 Eli Lilly and Company $6,730.63 06/02/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187887428
Principal investigator 1 ModernaTX, Inc. $500.00 05/28/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966085
Principal investigator 1 ModernaTX, Inc. $500.00 05/28/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966091
Principal investigator 1 ModernaTX, Inc. $2,100.13 05/23/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966039
Principal investigator 1 Bausch Health US, LLC $131.00 05/14/2025 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845027
Principal investigator 1 ModernaTX, Inc. $30.00 05/14/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $150.00 05/07/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514754
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,100.00 05/07/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514758
Principal investigator 1 Alnylam Pharmaceuticals Inc. $100.00 05/07/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514763
Principal investigator 1 PFIZER INC. $552.00 05/06/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228722872
Principal investigator 1 SANOFI US SERVICES INC. $4,600.00 04/28/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226128731
Principal investigator 1 ModernaTX, Inc. $1,343.79 04/23/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $107,168.80 04/16/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215514768
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 04/11/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215515042
Principal investigator 1 Genentech, Inc. $2,500.00 04/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626265
Principal investigator 1 Genentech, Inc. $10,000.00 04/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211626276
Principal investigator 1 Bausch Health US, LLC $2,250.00 04/02/2025 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845042
Principal investigator 1 Bausch Health US, LLC $1,900.00 04/02/2025 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845045
Principal investigator 1 Bausch Health US, LLC $1,300.00 04/02/2025 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845063
Principal investigator 1 Eli Lilly and Company $23,838.00 04/01/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187884282
Principal investigator 1 ModernaTX, Inc. $60.00 04/01/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966029
Principal investigator 1 ModernaTX, Inc. $500.00 04/01/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966097
Principal investigator 1 ModernaTX, Inc. $1,370.52 03/24/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966061
Principal investigator 1 ModernaTX, Inc. $260.50 03/21/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966075
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,596.67 03/18/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190309758
Principal investigator 1 Alnylam Pharmaceuticals Inc. $20,023.10 03/12/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215515030
Principal investigator 1 Genentech, Inc. $344.69 03/11/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626248
Principal investigator 1 Genentech, Inc. $1,098.70 03/11/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.96 03/07/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM No dispute reported 06/30/2026 1215515027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18,450.00 03/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM No dispute reported 06/30/2026 1215515015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $77,736.79 03/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM No dispute reported 06/30/2026 1215515019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 03/03/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM No dispute reported 06/30/2026 1215515024
Principal investigator 1 PFIZER INC. $15,014.40 02/22/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228759293
Principal investigator 1 Genentech, Inc. $2,500.00 02/20/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626289
Principal investigator 1 Genentech, Inc. $10,000.00 02/20/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211626303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66,141.95 02/19/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215515034
Principal investigator 1 Eli Lilly and Company $34,448.73 02/14/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187884280
Principal investigator 1 Eli Lilly and Company $91,324.28 02/14/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187884284
Principal investigator 1 Eli Lilly and Company $692,607.18 02/14/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886580
Principal investigator 1 Eli Lilly and Company $2,200.00 02/14/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187886582
Principal investigator 1 Eli Lilly and Company $3,561.88 02/14/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187886586
Principal investigator 1 PFIZER INC. $14,750.00 02/06/2025 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228723468
Principal investigator 1 PFIZER INC. $3,750.00 02/04/2025 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228753528
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215520480
Principal investigator 1 Eli Lilly and Company $360.00 01/31/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187887130
Principal investigator 1 Eli Lilly and Company $19,455.25 01/31/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187887422
Principal investigator 1 ModernaTX, Inc. $71,267.04 01/29/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252966015
Principal investigator 1 ModernaTX, Inc. $680.40 01/29/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252966099
Principal investigator 1 Eli Lilly and Company $506.75 01/27/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187884870
Principal investigator 1 Eli Lilly and Company $9,926.99 01/27/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187885518
Principal investigator 1 Eli Lilly and Company $858.02 01/27/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187887776
Principal investigator 1 Eli Lilly and Company $3,370.36 01/22/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885042
Principal investigator 1 Eli Lilly and Company $465,199.24 01/21/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187886578
Principal investigator 1 Eli Lilly and Company $11,540.93 01/09/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187885024
Principal investigator 1 Eli Lilly and Company $6,070.00 01/09/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187887424
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,239.89 01/09/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190309760
Principal investigator 1 Eli Lilly and Company $971,483.57 01/07/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187884286
Principal investigator 1 Eli Lilly and Company $205,542.11 01/07/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187887128
Principal investigator 1 Eli Lilly and Company $502,754.65 01/07/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187887420
Principal investigator 1 Eli Lilly and Company $704,881.98 01/07/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187887426
Principal investigator 1 Eli Lilly and Company $719.58 01/06/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187885022
Principal investigator 1 AstraZeneca UK Limited $41,711.85 01/03/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185545269
Principal investigator 1 Eli Lilly and Company $9,889.67 01/02/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885044
Principal investigator 1 Eli Lilly and Company $8,185.92 01/02/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885046
Principal investigator 1 Eli Lilly and Company $27,938.63 01/02/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187885884
Principal investigator 1 Eli Lilly and Company $857.26 01/02/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187887132